Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 VLP ... -based biotechnology company focusing on the research and ... generation antibody agents based upon a novel and ... 2015 Life Sciences Impact Grant Award from the ... grant, created by MCDED, is awarded to life ...
(Date:3/2/2015)... Calif. , March 2, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... financial and operating results on Tuesday, March 10, 2015 ... Company will host a conference call and webcast on ... 1:30 p.m. Pacific to discuss the results and recent ...
(Date:3/1/2015)... March 01, 2015 Market Publishers ... for quality market research promotion on Internet. MarketPublishers.com ... reports worked out by DataGroup Booksellers. , Natalie ... Publishers Ltd, commented on the recent partnership agreement ... Booksellers in our team of publishers. Since 1974, ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015 ... of the NCATS rare-diseases portfolio " in ... a new financing technique to reduce the risk ... diseases and potentially unlock new levels of funding ... The product of a unique collaboration between scientists ...
Breaking Biology Technology:VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... , , , , , , For transfection ... Features and benefits , , , , , , ... siRNA for effective gene silencing , Quick and easy setup , ... of RNase activity , , , , , ...
... , , , , , , For automated purification of genomic and mitochondrial ... , Format: , ... 8), QIAamp DNA Blood MDX Protocol, , ... Fresh or frozen whole blood (with common anticoagulants , such ...
... For , HotStarTaq DNA Polymerase , HotStarTaq Master Mix Kit , ... , Kit Contents , ... Technical Assistance , Safety Information , ... , HotStarTaq DNA Polymerase , ...
Cached Biology Technology:TransMessenger Transfection Reagent 2TransMessenger Transfection Reagent 3QIAamp DNA Blood BioRobot MDx Kit 2HotStarTaq PCR Handbook 2HotStarTaq PCR Handbook 3HotStarTaq PCR Handbook 4HotStarTaq PCR Handbook 5HotStarTaq PCR Handbook 6HotStarTaq PCR Handbook 7HotStarTaq PCR Handbook 8HotStarTaq PCR Handbook 9HotStarTaq PCR Handbook 10HotStarTaq PCR Handbook 11HotStarTaq PCR Handbook 12HotStarTaq PCR Handbook 13HotStarTaq PCR Handbook 14HotStarTaq PCR Handbook 15HotStarTaq PCR Handbook 16HotStarTaq PCR Handbook 17HotStarTaq PCR Handbook 18HotStarTaq PCR Handbook 19HotStarTaq PCR Handbook 20HotStarTaq PCR Handbook 21HotStarTaq PCR Handbook 22HotStarTaq PCR Handbook 23HotStarTaq PCR Handbook 24HotStarTaq PCR Handbook 25HotStarTaq PCR Handbook 26HotStarTaq PCR Handbook 27HotStarTaq PCR Handbook 28HotStarTaq PCR Handbook 29HotStarTaq PCR Handbook 30HotStarTaq PCR Handbook 31HotStarTaq PCR Handbook 32HotStarTaq PCR Handbook 33
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... of newborns, blood samples stored in a Michigan bio-bank, ... practice of using the blood spots for medical research. ... public policy decisions and develop an improved consent process ... said Ann Mongoven, an assistant professor in MSU,s Center ...
... squids as different as they may look, they ... the phylum Mollusca , also called molluscs. An ... Professor Ken Halanych, USA, with the participation of Johannes ... into the relationships among different molluscs as part of ...
... 2011 SynCardia Systems, Inc. ( www.syncardia.com ), manufacturer ... announced today that University Hospital of Nantes successfully transplanted ... days of support. Mrs. Mouche is a French gypsy ... 40 km from Nantes. "We first implanted ...
Cached Biology News:MSU engages public on using newborn blood spots for research 2Research into molluscan phylogeny reveals deep animal relationship of snails and mussels 2Research into molluscan phylogeny reveals deep animal relationship of snails and mussels 3SynCardia's Total Artificial Heart Rescues LVAD Patient with Right Ventricular Failure 2SynCardia's Total Artificial Heart Rescues LVAD Patient with Right Ventricular Failure 3
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
Biology Products: